SCHEDULE: Sabby Entities Disclose 4.9% Passive Stake in Transcode

Sabby Management, Sabby Volatility Warrant Master Fund, and Hal Mintz have jointly disclosed a passive 4.9% beneficial ownership in Transcode Therapeutics, Inc. common stock.

Summary

• Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz collectively reported beneficial ownership of 41,601 shares of Transcode Therapeutics, Inc. Common Stock.
• This ownership represents 4.9% of the class of securities.
• The reporting persons share both voting and dispositive power over all 41,601 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a previous filing of a similar nature.
• The securities were not acquired or held for the purpose of changing or influencing the control of Transcode Therapeutics, Inc.

Sentiment

Score: 5

Explanation: This is a routine disclosure of a passive ownership stake, providing factual information without inherent positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive ownership stake held by institutional investors and an individual.

Key Dates

Keywords

Transcode Therapeutics, Sabby Management, Sabby Volatility Warrant Master Fund, Hal Mintz, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Passive Investment